@article{3103655,
    title = "Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure",
    author = "Seferović, P.M. and Fragasso, G. and Petrie, M. and Mullens, W. and Ferrari, R. and Thum, T. and Bauersachs, J. and Anker, S.D. and Ray, R. and Çavuşoğlu, Y. and Polovina, M. and Metra, M. and Ambrosio, G. and Prasad, K. and Seferović, J. and Jhund, P.S. and Dattilo, G. and Čelutkiene, J. and Piepoli, M. and Moura, B. and Chioncel, O. and Ben Gal, T. and Heymans, S. and Jaarsma, T. and Hill, L. and Lopatin, Y. and Lyon, A.R. and Ponikowski, P. and Lainščak, M. and Jankowska, E. and Mueller, C. and Cosentino, F. and Lund, L.H. and Filippatos, G.S. and Ruschitzka, F. and Coats, A.J.S. and Rosano, G.M.C.",
    journal = "European Journal of Heart Failure",
    year = "2020",
    volume = "22",
    number = "11",
    pages = "1984-1986",
    publisher = "John Wiley and Sons Ltd",
    doi = "10.1002/ejhf.2026",
    keywords = "canagliflozin;  dapagliflozin;  empagliflozin;  ertugliflozin;  sodium glucose cotransporter 2 inhibitor;  SLC5A2 protein, human;  sodium glucose cotransporter 2, all cause mortality;  Article;  cardiovascular mortality;  cardiovascular risk;  chronic kidney failure;  diabetic patient;  estimated glomerular filtration rate;  Europe;  follow up;  heart failure;  high risk patient;  hospitalization;  human;  kidney function;  non insulin dependent diabetes mellitus;  outcome assessment;  priority journal;  risk reduction;  heart failure;  metabolism, Diabetes Mellitus, Type 2;  Heart Failure;  Humans;  Sodium-Glucose Transporter 2;  Sodium-Glucose Transporter 2 Inhibitors",
    abstract = "The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium–glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:. • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus. © 2020 European Society of Cardiology"
}